In this episode, Béatrice Mathieu, senior reporter and specialist in economic issues, explains everything about this major issue for France’s health sovereignty.
FIND ALL THE EPISODES OF THE MAGNIFIER
Listen to this episode and subscribe to La Loupe on Apple Podcasts, Spotify, Deezer, Google Podcasts, Addict Podcast And Amazon Music.
The team: Charlotte Baris (presentation and writing), Jules Krot (editing and direction)
Credits: Elysée, LCP, Brut, RTL, France Culture
Music and dressing: Emmanuel Herschon / Studio Torrent
Logo: Jérémy Cambour
How to listen to a podcast? follow the leader.
Charlotte Baris: In June 2020, in the midst of the Covid pandemic and while restrictions were still significant, Emmanuel Macron assured: “We must continue to produce in our country and on our continent.”
Faced with the urgency of developing vaccines, faced with difficulties in supplying masks or hydroalcoholic gel, France has shown its dependence on foreign companies. So, in the premises of the Sanofi pharmaceutical laboratory near Lyon, the President of the Republic assures that France is committed to regaining health sovereignty.
Four years later, Sanofi announced that it was negotiating with an American investment fund to sell its branch which notably produces Doliprane. And again the concern about the independence of our medicines is growing…
To go further
Doliprane soon to be sold by Sanofi? Behind the scenes of a politically explosive operation
Doliprane: this article of the monetary and financial code which could block the sale
Upsa and 100% French paracetamol: behind the scenes of an improbable battle